53432
document
Impact of antisecretory treatment on respiratory symptoms of gastroesophageal reflux disease in children . The effect of antisecretory treatment on extraesophageal symptoms of gastroesophageal reflux disease was evaluated . Seventy-eight children presenting with typical and extraesophageal symptoms of gastroesophageal reflux disease underwent a multichannel intraluminal impedance and pH monitoring ( MII/pH ) . Children with a positive MII/pH were randomly treated with proton pump inhibitors ( PPIs ) or histamine H ( 2 ) -receptor antagonists ( H ( 2 ) RAs ) during 3 months . At the end of the treatment period , all patients were recalled . A second treatment period of 3 months was given to those patients who were not symptom-free after 3 months . Thirty-five of the forty-one ( 85.4 % ) children with a pathologic MII/pH presented with extraesophageal symptoms and were treated with PPIs ( omeprazole ; n:19 ) or H ( 2 ) RAs ( ranitidine ; n:16 ) for 12 weeks . After 3 months , 11/19 ( 57.9 % ) PPI-treated patients had a complete resolution of symptoms ; 6/8 nonresponders were treated with PPI for another 3 months and became all symptom-free . The other two underwent a Nissen fundoplication . Only 5/16 ( 31.2 % ) patients treated with H ( 2 ) RAs had a complete resolution of symptoms after 3 months ; 1/11 was treated again with H ( 2 ) RAs during 3 months , and 10/11 were changed to PPIs . In 3/10 , a partial resolution of symptoms was achieved , while in 7/10 , a complete remission was obtained ( P < 0.05 ) . Antisecretory reflux treatment improves extraesophageal reflux symptoms . The efficacy of PPIs is superior to that of H ( 2 ) RAs in these children .
53433
Intervention_Pharmacological
antisecretory treatment
53434
Intervention_Pharmacological
antisecretory treatment
53435
Intervention_Pharmacological
proton pump inhibitors ( PPIs )
53436
Intervention_Pharmacological
histamine H ( 2 ) -receptor antagonists ( H ( 2 ) RAs )
53437
Intervention_Pharmacological
PPIs ( omeprazole
53438
Intervention_Pharmacological
H ( 2 ) RAs ( ranitidine
53439
Intervention_Pharmacological
PPI-treated
53440
Intervention_Pharmacological
PPI
53441
Intervention_Pharmacological
H ( 2 ) RAs
53442
Intervention_Pharmacological
H ( 2 ) RAs
53443
Intervention_Pharmacological
PPIs
53444
Intervention_Pharmacological
Antisecretory reflux treatment
53445
Intervention_Pharmacological
PPIs
53446
Intervention_Pharmacological
H ( 2 ) RAs
53447
Outcome_Physical
respiratory symptoms of gastroesophageal reflux disease
53448
Outcome_Other
effect
53449
Outcome_Physical
extraesophageal symptoms of gastroesophageal reflux disease
53450
Outcome_Physical
extraesophageal symptoms
53451
Outcome_Physical
resolution of symptoms
53452
Outcome_Physical
symptom-free
53453
Outcome_Physical
complete resolution of symptoms
53454
Outcome_Physical
partial resolution of symptoms
53455
Outcome_Physical
complete remission
53456
Outcome_Physical
extraesophageal reflux symptoms
53457
Outcome_Other
efficacy